Crinetics Pharmaceuticals Inc’s recently made public that its Officer DANA J PIZZUTI acquired Company’s shares for reported $0.2 million on Feb 03 ’25. In the deal valued at $39.07 per share,5,000 shares were bought.
Then, Pizzuti Dana sold 15,000 shares, generating $781,350 in total proceeds. Upon selling the shares at $52.09, the Chief Med and Dev Officer now owns 29,248 shares.
Before that, DANA J PIZZUTI bought 15,000 shares. Crinetics Pharmaceuticals Inc shares valued at $781,323 were divested by the Officer at a price of $52.09 per share.
Wolfe Research initiated its Crinetics Pharmaceuticals Inc [CRNX] rating to a Peer perform in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in late January from “a Hold” to “a Buy”. Citigroup began covering CRNX with “Buy” recommendation on March 06, 2024. Morgan Stanley started covering the stock on January 16, 2024. It rated CRNX as “an Overweight”.
Price Performance Review of CRNX
On Tuesday, Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] saw its stock jump 4.15% to $40.40. Over the last five days, the stock has gained 5.70%. Crinetics Pharmaceuticals Inc shares have fallen nearly -20.99% since the year began. Nevertheless, the stocks have risen 8.57% over the past one year. While a 52-week high of $62.53 was reached on 01/03/25, a 52-week low of $35.51 was recorded on 01/14/25. SMA at 50 days reached $49.23, while 200 days put it at $50.52.
Levels Of Support And Resistance For CRNX Stock
The 24-hour chart illustrates a support level at 39.07, which if violated will result in even more drops to 37.74. On the upside, there is a resistance level at 41.17. A further resistance level may holdings at 41.94. The Relative Strength Index (RSI) on the 14-day chart is 41.30, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.15, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 18.45%. Stochastics %K at 72.47% indicates the stock is a holding.
How much short interest is there in Crinetics Pharmaceuticals Inc?
A steep rise in short interest was recorded in Crinetics Pharmaceuticals Inc stocks on 2025-01-15, growing by 0.92 million shares to a total of 7.17 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 6.25 million shares. There was a rise of 12.79%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 21, 2023 when Jefferies began covering the stock and recommended ‘”a Hold”‘ rating along with a $35 price target.
